These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 31601648)

  • 21. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer.
    Ackroyd SA; Thomas S; Angel C; Moore R; Meacham PJ; DuBeshter B
    J Robot Surg; 2018 Jun; 12(2):245-250. PubMed ID: 28631233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
    Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
    Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
    Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
    Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
    Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
    Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
    J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA
    Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
    Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Persenaire C; Pyrzak A; Barber EL
    J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial).
    Chiva L; Ordás P; Martin-Calvo N; Aramendia JM; Sanchez Lorenzo L; Gallego Martínez A; Vizcay Á; Minguez JA; Manzour N; Vázquez-Vicente D; Chacon E; Castellanos T; Gonzalez Martin A
    Int J Gynecol Cancer; 2024 Jun; 34(6):942-945. PubMed ID: 38479803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
    Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
    Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
    Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
    J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
    Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.